We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that they have secured a $10 million investment from Pavilion Capital, a Singapore-based investment institution.